Publications in collaboration with researchers from GlaxoSmithKline (United Kingdom) (70)

2024

  1. 4CMenB journey to the 10-year anniversary and beyond

    Human Vaccines and Immunotherapeutics, Vol. 20, Núm. 1

  2. Airway and Blood Monocyte Transcriptomic Profiling Reveals an Antiviral Phenotype in Infants With Severe Respiratory Syncytial Virus Infection

    Journal of Infectious Diseases, Vol. 229, pp. S100-S111

  3. Disparate kinetics in immune response of two different Haemophilus influenzae type b conjugate vaccines: Immunogenicity and safety observations from a randomized controlled phase IV study in healthy infants and toddlers using a 2+1 schedule

    Human Vaccines and Immunotherapeutics, Vol. 20, Núm. 1

  4. Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 78, Núm. 6, pp. 1732-1744

  5. Genome-wide Association Study of Susceptibility to Respiratory Syncytial Virus Hospitalization in Young Children <5 Years of age

    Journal of Infectious Diseases, Vol. 230, Núm. 2, pp. e333-e341

  6. Urgent Need to Understand and Prevent Gonococcal Infection: From the Laboratory to Real-World Context

    The Journal of infectious diseases, Vol. 230, Núm. 4, pp. e758-e767

2023

  1. Publisher Correction: The Value of Rotavirus Vaccination in Europe: A Call for Action (Infectious Diseases and Therapy, (2023), 12, 1, (9-29), 10.1007/s40121-022-00697-7)

    Infectious Diseases and Therapy

  2. Rule of Prevention: a potential framework to evaluate preventive interventions for rare diseases

    Journal of Market Access and Health Policy, Vol. 11, Núm. 1

  3. Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus (RSV) Vaccine in Healthy RSV-Seropositive Children 12-23 Months of Age

    The Journal of infectious diseases, Vol. 227, Núm. 11, pp. 1293-1302

  4. Societal Preferences for Meningococcal B Vaccination in Children: A Discrete Choice Experiment in Spain

    Infectious Diseases and Therapy, Vol. 12, Núm. 1, pp. 157-175

  5. The Value of Rotavirus Vaccination in Europe: A Call for Action

    Infectious Diseases and Therapy

  6. Use of expanded Neisseria meningitidis serogroup B panels with the serum bactericidal antibody assay for the evaluation of meningococcal B vaccine effectiveness

    Expert review of vaccines, Vol. 22, Núm. 1, pp. 738-748

2022

  1. Age-Specific Estimates of Respiratory Syncytial Virus-Associated Hospitalizations in 6 European Countries: A Time Series Analysis

    Journal of Infectious Diseases, Vol. 226, pp. S29-S37

  2. Clinical and Viral Factors Associated With Disease Severity and Subsequent Wheezing in Infants With Respiratory Syncytial Virus Infection

    The Journal of infectious diseases, Vol. 226, Núm. 1, pp. S45-S54

  3. Evolving strategies for meningococcal vaccination in Europe: Overview and key determinants for current and future considerations

    Pathogens and Global Health, Vol. 116, Núm. 2, pp. 85-98

  4. Global Disease Burden of Respiratory Syncytial Virus in Preterm Children in 2019: A Systematic Review and Individual Participant Data Meta-Analysis Protocol

    Journal of Infectious Diseases, Vol. 226, pp. S135-S141

  5. Incidence of herpes zoster and its complications in ≥ 50-year-old Spanish adults: A prospective cohort study

    Vacunas, Vol. 23, Núm. 3, pp. 165-173

  6. Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination

    Open Forum Infectious Diseases, Vol. 9, Núm. 10

  7. Patient Involvement in RSV Research: Towards Patients Setting the Research Agenda

    Journal of Infectious Diseases, Vol. 226, pp. S130-S134

  8. Range of invasive meningococcal disease sequelae and health economic application – a systematic and clinical review

    BMC Public Health, Vol. 22, Núm. 1